EMA Recommends Granting a Marketing Authorisation for Lurbinectedin By Ogkologos - April 30, 2026 68 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Sun Safety May 20, 2022 Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery November 30, 2018 GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... September 17, 2020 Ponatinib Effectively Treats Newly Diagnosed Acute Lymphoblastic Leukemia: The ASCO Plenary... February 14, 2023 Load more HOT NEWS FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung... FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease Why it’s difficult to estimate the number of extra cancer deaths... Grieving for Your Old Life After Cancer
